Melika Amoukhteh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Melika Amoukhteh has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Sherief Ghozy
Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA
3 shared publications - Amir Hassankhani
Department of Graduate Medical Education, Valley Health System, Las Vegas, NV, USA
2 shared publications - David F. Kallmes
Department of Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905
2 shared publications Parya Valizadeh
From the Department of Radiology (J.C., S.G., P.V., A. Hasanzadeh, M.A., P.J., A. Hassankhani, A.A., D.F.K.), Mayo Clinic Rochester, Minnesota
2 shared publicationsPayam Jannatdoust
From the Department of Radiology (J.C., S.G., P.V., A. Hasanzadeh, M.A., P.J., A. Hassankhani, A.A., D.F.K.), Mayo Clinic Rochester, Minnesota
2 shared publications- Ramanathan Kadirvel
Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA
2 shared publications
Latest Publications
- 27 February 2025
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 46 (3) , 510-516
Initial Experience with the Pipeline Vantage Flow Diverter for Intracranial Aneurysms: A Systematic Review and Meta-Analysis
Background: The Pipeline Vantage Flow diverter (Vantage) is the latest generation of Pipeline flow diverters introducing Cobalt-chronium drawn-filled tubing and 48 to 68 wires. Purpose: We report the initial safety and efficacy of Vantage in treating intracranial aneurysms in the published literature. Data Sources: A systematic review and meta-analysis was conducted according to established protocols. Searches were conducted in PubMed, Scopus, Web-of-Science, and Embase databases up to December 2023. Original studies reporting treatment outcomes for intracranial aneurysms using Vantage in more than five patients were included. Study Selection: Pooled data from 5 studies (373 patients, 418 aneurysms) were analyzed. Data Analysis: Outcomes of interest were: technical success, occlusion rates, complication outcomes and mortality. Data Synthesis: A technical success rate of 99.2% (95% CI: 98.29%–100%) was found. In unruptured cases, success rate was 378/383 (99.6%) versus 17/20 (85.0%) in ruptured cases (P < .01). Complete occlusion rate was 74.3% (95% CI: 67.43%–80.59%), with no significant difference between ruptured and unruptured cases (P = 0.72); median of follow up 6 months. Overall mortality rate was 1.2% (95% CI: 0.01%–3.64%), significantly higher in ruptured (18.6%; 95% CI: 5.13%–36.26%) versus unruptured cases (0.23%; 95% CI: 0%–1.36%) (P < 0.01). Hemorrhagic complications occurred at 1% (95% CI: 0%–3.36%) pooled rate. Thromboembolic complications were reported at 6.1% (95% CI: 2.60%–10.73%), decreasing to 4.35% (95% CI: 1.91%–7.54%) after excluding one outlier study. Limitations: Only five studies, some with small number of patients, were included in this meta-analysis which may limit the generalizability of our findings. The absence of long term follow-up also limits the assessment of treatment durability. Conclusions: In this meta-analysis, we found that Vantage initial experience is similar to previous version of the Pipeline Embolization Device in terms of safety and efficacy for treatment of intracranial aneurysms, in particular unruptured aneurysms. Further prospective and comparative studies with patient outcome data specific to aneurysm location are needed to confirm the safety and efficacy of Vantage.
- 27 February 2025
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 46 (3) , 510-516
Initial Experience with the Pipeline Vantage Flow Diverter for Intracranial Aneurysms: A Systematic Review and Meta-Analysis
Background: The Pipeline Vantage Flow diverter (Vantage) is the latest generation of Pipeline flow diverters introducing Cobalt-chronium drawn-filled tubing and 48 to 68 wires. Purpose: We report the initial safety and efficacy of Vantage in treating intracranial aneurysms in the published literature. Data Sources: A systematic review and meta-analysis was conducted according to established protocols. Searches were conducted in PubMed, Scopus, Web-of-Science, and Embase databases up to December 2023. Original studies reporting treatment outcomes for intracranial aneurysms using Vantage in more than five patients were included. Study Selection: Pooled data from 5 studies (373 patients, 418 aneurysms) were analyzed. Data Analysis: Outcomes of interest were: technical success, occlusion rates, complication outcomes and mortality. Data Synthesis: A technical success rate of 99.2% (95% CI: 98.29%–100%) was found. In unruptured cases, success rate was 378/383 (99.6%) versus 17/20 (85.0%) in ruptured cases (P < .01). Complete occlusion rate was 74.3% (95% CI: 67.43%–80.59%), with no significant difference between ruptured and unruptured cases (P = 0.72); median of follow up 6 months. Overall mortality rate was 1.2% (95% CI: 0.01%–3.64%), significantly higher in ruptured (18.6%; 95% CI: 5.13%–36.26%) versus unruptured cases (0.23%; 95% CI: 0%–1.36%) (P < 0.01). Hemorrhagic complications occurred at 1% (95% CI: 0%–3.36%) pooled rate. Thromboembolic complications were reported at 6.1% (95% CI: 2.60%–10.73%), decreasing to 4.35% (95% CI: 1.91%–7.54%) after excluding one outlier study. Limitations: Only five studies, some with small number of patients, were included in this meta-analysis which may limit the generalizability of our findings. The absence of long term follow-up also limits the assessment of treatment durability. Conclusions: In this meta-analysis, we found that Vantage initial experience is similar to previous version of the Pipeline Embolization Device in terms of safety and efficacy for treatment of intracranial aneurysms, in particular unruptured aneurysms. Further prospective and comparative studies with patient outcome data specific to aneurysm location are needed to confirm the safety and efficacy of Vantage.
- 25 September 2024
- Published by Elsevier in Academic Radiology
- Vol. 31 (11) , 4383-4385
Diversity Patterns in Interventional Radiology Residency Applicants
- 25 September 2024
- Published by Elsevier in Academic Radiology
- Vol. 31 (11) , 4383-4385
Diversity Patterns in Interventional Radiology Residency Applicants
- Open Access
- 20 July 2024
- Published by MDPI AG in Brain Sciences
- Vol. 14 (7) , 728
The Utilization of Systematic Reviews and Meta-Analyses in Stroke Guidelines
Background: Stroke guideline statements are important references for clinicians due to the rapidly evolving nature of treatments. Guideline statements should be informed by up-to-date systematic reviews (SRs) and meta-analyses (MAs) because they provide the highest level of evidence. To investigate the utilization of SRs/MAs in stroke management guidelines, we conducted a literature review of guidelines and extracted relevant information regarding SRs/MAs. Methods: A literature review was conducted in PubMed with supplementation using the Trip medical database with the term “stroke” as the target population, followed by using the filter “guidelines”. We extracted the number of included SRs/MAs, the years of publication, the country of origin, and other characteristics of interest. Descriptive statistics were generated using the R software version 4.2.1. Results: We included 27 guideline statements. The median number of overall SRs or MAs within the guidelines was 4.0 (interquartile range [IQR] = 2–9). For MAs only, the median number included in the guidelines was 3.0 (IQR = 2.0–5.5). Canadian guidelines had the oldest citations, with a median gap of 12.0 (IQR = 5.2–18.0) years for the oldest citation, followed by European (median = 12; IQR = 9.5–13.5) and US (median = 10.0; IQR = 5.2–16) guidelines. Conclusions: Stroke guideline writing groups and issuing bodies should devote greater effort to the inclusion of up-to-date SRs/MAs in their guideline statements so that clinicians can reference recent data with the highest level of evidence.
- 20 July 2024
- Published by MDPI AG in Brain Sciences
- Vol. 14 (7) , 728
Open AccessThe Utilization of Systematic Reviews and Meta-Analyses in Stroke Guidelines
Background: Stroke guideline statements are important references for clinicians due to the rapidly evolving nature of treatments. Guideline statements should be informed by up-to-date systematic reviews (SRs) and meta-analyses (MAs) because they provide the highest level of evidence. To investigate the utilization of SRs/MAs in stroke management guidelines, we conducted a literature review of guidelines and extracted relevant information regarding SRs/MAs. Methods: A literature review was conducted in PubMed with supplementation using the Trip medical database with the term “stroke” as the target population, followed by using the filter “guidelines”. We extracted the number of included SRs/MAs, the years of publication, the country of origin, and other characteristics of interest. Descriptive statistics were generated using the R software version 4.2.1. Results: We included 27 guideline statements. The median number of overall SRs or MAs within the guidelines was 4.0 (interquartile range [IQR] = 2–9). For MAs only, the median number included in the guidelines was 3.0 (IQR = 2.0–5.5). Canadian guidelines had the oldest citations, with a median gap of 12.0 (IQR = 5.2–18.0) years for the oldest citation, followed by European (median = 12; IQR = 9.5–13.5) and US (median = 10.0; IQR = 5.2–16) guidelines. Conclusions: Stroke guideline writing groups and issuing bodies should devote greater effort to the inclusion of up-to-date SRs/MAs in their guideline statements so that clinicians can reference recent data with the highest level of evidence.
- Open Access
- 30 November 2021
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 19 (4) , 712-720
Effects of Iron Supplementation on Attention Deficit Hyperactivity Disorder in Children Treated with Methylphenidate
Sepehr Tohidi, Elham Bidabadi, Mohammad-Javad Khosousi, Melika Amoukhteh, Maryam Kousha, Parham Mashouf, Tamkin Shahraki. Clin Psychopharmacol Neurosci 2021;19:712-20. https://doi.org/10.9758/cpn.2021.19.4.712
- 30 November 2021
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 19 (4) , 712-720
Open AccessEffects of Iron Supplementation on Attention Deficit Hyperactivity Disorder in Children Treated with Methylphenidate
Sepehr Tohidi, Elham Bidabadi, Mohammad-Javad Khosousi, Melika Amoukhteh, Maryam Kousha, Parham Mashouf, Tamkin Shahraki. Clin Psychopharmacol Neurosci 2021;19:712-20. https://doi.org/10.9758/cpn.2021.19.4.712